Eplehef 50 Tablet contains Eplerenone 50 mg, a selective aldosterone receptor antagonist indicated primarily for the management of hypertension and heart failure post-myocardial infarction. Eplerenone functions by competitively blocking aldosterone binding at mineralocorticoid receptors in the distal renal tubules, promoting sodium and water excretion while conserving potassium, thereby reducing blood volume and systemic vascular resistance. This mechanism contributes to its efficacy in lowering blood pressure and mitigating cardiac remodeling associated with heart failure. Eplehef 50 is typically administered orally once daily, with dosage adjustments based on patient response and renal function. It is contraindicated in patients with hyperkalemia, significant renal impairment, or hypersensitivity to the active substance. Caution is advised when co-administered with potassium supplements, potassium-sparing diuretics, or other agents that increase serum potassium, due to the risk of hyperkalemia. Regular monitoring of serum electrolytes, renal function, and blood pressure is recommended during therapy. Common adverse effects include hyperkalemia, dizziness, and gastrointestinal disturbances. Eplehef 50 Tablet should be used under medical supervision, with adherence to prescribed dosing to optimize therapeutic outcomes and minimize potential risks.